Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine

AIDS

Volumn 16, Issue 17, 2002, Pages 2352-2354

  Núñez, Marina ^a   Pérez Olmeda, Mayte ^a   Díaz, Beatriz ^a   Ríos, Pilar ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0037159877     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211220-00023     Document Type: Article

References (13)

1. Carton J, Maradona J, Asensi V, Rodríguez M, Martínez A. Lamivudine for chronic hepatitis B and HIV co-infection. AIDS 1999; 13:1002-1003.
2. Piroth L, Grappin M, Buisson M, Duong M, Portier H, Chavanet P. Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 23:356-357.
3. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C. Hepatitis B virus co-infection in HIV-infected subjects. AIDS Rev 2002; 4:3-10.
4. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus infection in coinfected patients receiving lamivudine as a component of anti-HIV regimens. Clin Infect Dis 2001; 32:963-969.
5. Benhamou Y, Bochet M, Thibaut V, Di Martino V, Charlotte F, Azria F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999; 30:1302-1306.
6. Wolters L, Niesters H, Hansen B, van der Ende M, Kroon F, Richeter C, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with HIV in a Dutch cohort. J Clin Virol 2002; 24:173-181.
7. Pillay D, Cane P, Ratcliffe D, Atkins M, Cooper D, for the CAESAR coordinating committee. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: An analysis of the CAESAR study. AIDS 2000; 14:1111-1116.
8. Thabut D, Thibault V, Benhamou Y, Bernard B, Aubron-Olivier C, Poynard T, Di Martino V. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. AIDS 2001; 15:2463-2644.
9. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in patients coinfected with HIV. Gastroenterology 2002; 122: 244-245.
10. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepatol 2000; 7:161-165.
11. Cooper D, Cheng A, Coakley D, Sayre J, Zhong L, Chen S, et al. Anti-HBV activity of tenofovir disoproxil fumarate in lamivudine-experienced HIV/HBV coinfected patients. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Abstract 124].
12. Benhamou Y, Bochet M, Tubiana R, Poynard T. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients coinfected with HIV/HBV. In: 37th Annual Meeting of the European Association for the Study of the Liver. Madrid, Spain, April 2002 [Abstract 641].
13. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet M, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001; 358:718-723.